AGP Executive Report
Last update: 11 hours agoRheumatology Drug Update (Italy-relevant): The phase 3 COURAGE-RA trial presented at EULAR 2026 reports zemprocitinib (a selective JAK1 inhibitor) hitting key endpoints in moderate-to-severe rheumatoid arthritis patients who didn’t respond well to biologics, with Rome rheumatologist Roberta Priori highlighting the need for better oral options. Public Health & Climate: A study on heat-wave behavior adds to growing concerns that extreme heat can impair learning and decision-making in animals—raising risks for food-finding and survival as climate change makes hot spells more frequent. Infectious Disease Research: A new analysis suggests past malaria exposure may have been linked to milder COVID-19 outcomes in Africa, pointing to immune “cross-talk” that could reduce severe inflammatory lung damage. Dermatology/Beauty Tech: Magnetic Tattoo Removal inventor Linda Paradis presented her patent-based approach at a Dubai dermatology conference, positioning it as an option for patients who may not be good candidates for laser tattoo removal. Sports Health Angle (Heat & Performance): Roland Garros is being shaped by a first-week heat wave, with players reporting cramping and needing medical attention, while mental strain also shows up in surprising results.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
